- Home
- RMCO vs NRXP Comparison
RMCO vs NRXP Comparison
Compare RMCO & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCO
- NRXP
- Stock Information
- Founded
- RMCO 2021
- NRXP 2015
- Country
- RMCO United States
- NRXP United States
- Employees
- RMCO N/A
- NRXP N/A
- Industry
- RMCO Multi-Sector Companies
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- RMCO Miscellaneous
- NRXP Health Care
- Exchange
- RMCO Nasdaq
- NRXP Nasdaq
- Market Cap
- RMCO 17.2M
- NRXP 14.8M
- IPO Year
- RMCO N/A
- NRXP N/A
- Fundamental
- Price
- RMCO $1.07
- NRXP $1.16
- Analyst Decision
- RMCO
- NRXP Strong Buy
- Analyst Count
- RMCO 0
- NRXP 3
- Target Price
- RMCO N/A
- NRXP $31.33
- AVG Volume (30 Days)
- RMCO 10.0K
- NRXP 153.3K
- Earning Date
- RMCO 11-22-2024
- NRXP 11-18-2024
- Dividend Yield
- RMCO N/A
- NRXP N/A
- EPS Growth
- RMCO N/A
- NRXP N/A
- EPS
- RMCO N/A
- NRXP N/A
- Revenue
- RMCO $644,293.00
- NRXP N/A
- Revenue This Year
- RMCO N/A
- NRXP N/A
- Revenue Next Year
- RMCO N/A
- NRXP N/A
- P/E Ratio
- RMCO N/A
- NRXP N/A
- Revenue Growth
- RMCO 126.99
- NRXP N/A
- 52 Week Low
- RMCO $0.70
- NRXP $1.10
- 52 Week High
- RMCO $5.90
- NRXP $7.33
- Technical
- Relative Strength Index (RSI)
- RMCO 53.62
- NRXP 33.72
- Support Level
- RMCO $1.04
- NRXP $1.23
- Resistance Level
- RMCO $1.19
- NRXP $1.30
- Average True Range (ATR)
- RMCO 0.08
- NRXP 0.10
- MACD
- RMCO 0.00
- NRXP 0.00
- Stochastic Oscillator
- RMCO 57.14
- NRXP 12.12
About RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.